Newamsterdam Pharma Company N.V. (NAMS) Stock Price, Quote & News

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 35 206 2971

Website: www.newamsterdampharma.com

Address:

Gooimeer 2-35, Naarden, Netherlands

masonat Apr. 3 at 1:34 PM

$NAMS Pooled safety analysis for obicetrapib published. Believe it or not, I think obi has a real shot at demonstrating statistically significant **better safety than placebo** (the first LLT ever?) in PREVAIL. https://www.sciencedirect.com/science/article/pii/S2666667726001418?via%3Dihub

1 · Reply

TrendEdgeLogan Mar. 31 at 5:21 PM

$GH $KYMR $IMNM $NAMS $SOPH OCS PVLA ZYM SRZN ^^ best of the best healthcare / biotech names right now

0 · Reply

HAGAKURE Mar. 31 at 4:04 PM

$NAMS no revenues, no earnings … nothing here !!! Why such value ???

0 · Reply

masonat Mar. 31 at 11:51 AM

$NAMS This AI gives prevail just 37% probability of success. Always good to read the bear case to test your thesis. https://warpspeed.sh/forecast/exp-nams

1 · Reply

masonat Mar. 29 at 12:55 PM

$NAMS "What justifies a 3.5B valuation?" Have you ever been in a stock that's been bought out? I've had three just in the last four months (and I generally only hold 5-7 positions at a time). TERN: 6.7B BO with no revenue, P3 trials not even started yet. VTYX: 1.2B BO no revenue, no P3 trials initiated or even planned. CDTX: 9.2B BO with no revenue and no P3 results yet. Plenty more examples that I wasn't involved in. That's how this works. Pharma buys attractive assets for premium valuations, usually before they even get approved. If obicetrapib CVOT has good results, this will be a very high value target.

0 · Reply

Phasedrei Mar. 29 at 8:06 AM

$NAMS Part 2 9. Starting in November 2027, with a very large clinical trial, then 1 pill (triple therapy) as a game-changer—the required bioequivalence studies for both (Rosu and Ator) have already been completed All of this would really give me pause OBI is not a miracle drug, and even that wouldn’t sell itself! Hmmm, I keep asking myself: What in God’s name justifies a $3.5 billion valuation for NAMS? What happens here if the inflated expectations aren’t met? I wouldn’t feel good about this! But maybe the few board participants here are only interested in the science and aren’t here for the investment.

1 · Reply

Phasedrei Mar. 29 at 8:02 AM

$NAMS Obicetrapib works! But let’s summarize a few facts: 1. Currently, there are no long-term MACE 4 endpoint data—proof must first be provided that OBI also leads to an acceptable and significant reduction in cardiovascular events. Long-term: that’s all that matters! No CETP inhibitor has impressively achieved this before 2. No approval in the U.S. yet—expected by the end of 2027 3. Hardly any significant licensing revenue after approval in Germany by BC in the first year, due to a lack of GBA negotiations and health insurance discounts 4. No proprietary distribution structure or 5. No BA partner to date 6. No health insurance acceptance 7. No guideline recommendation in the foreseeable future 8. Already facing strong competition from widely accepted (statins or ezetimibe) and continuously growing (BA or PcsK9) therapies;

0 · Reply

Phasedrei Mar. 28 at 5:35 PM

$NAMS Okay, a 12% risk reduction after 7 years Hmm, I'm really looking forward to the PEVAIL data Without MACE data, you're just flying blind By the way: Triple pill (Ator/Rosu + Ezetemib + Bempedoic acid) coming in November 2027 60–70% LDL reduction and massive hsCRP reduction; and those are in the guidelines and have been negotiated with health insurers next guideline update in 5–6 years I’m curious to see who will market Obicetrapib in the US Translated with DeepL.com (free version)

1 · Reply

masonat Mar. 28 at 12:14 PM

$NAMS Anacetrapib increased HDL 100%+ Longer follow-up showed *more* benefit, not less. Of course, the MACE benefit was largely driven by LDL, but the high HDL didn't have any negative impact.

0 · Reply

Phasedrei Mar. 28 at 10:33 AM

$NAMS When can we expect the long-term data from the endpoint study? Annual data aren’t very meaningful; I am very curious to see the effects of an approximately 130% increase in HDL in long-term follow-up; HDL levels above 100 could have a pro-inflammatory effect and negatively outweigh other benefits of the substance; these results have also only emerged later in long-term follow-up for all other CETP inhibitors. what about anti-inflammatory effects? LPa—the slight reduction is a nice side effect, but you don’t get approval for that, and for LPa there will be other, very effective approaches in the foreseeable future: e.g., pelacarsen Translated with DeepL.com (free version)

0 · Reply

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 23, 2026, 8:00 AM EDT - 13 days ago

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

Mar 18, 2026, 1:35 AM EDT - 18 days ago

AMG TimesSquare Small Cap Growth Fund Q4 2025 Performance Insights

ABVX AI AXGN BOOT CBLL CWST IPO

Feb 25, 2026, 8:00 AM EST - 5 weeks ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Feb 18, 2026, 7:00 AM EST - 6 weeks ago

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 4, 2026, 8:00 AM EST - 2 months ago

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

Jan 9, 2026, 8:00 AM EST - 3 months ago

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

Dec 3, 2025, 6:33 PM EST - 4 months ago

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 25, 2025, 8:00 AM EST - 4 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

Nov 16, 2025, 10:30 AM EST - 5 months ago

NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating

Nov 5, 2025, 8:00 AM EST - 5 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Oct 30, 2025, 8:00 AM EDT - 5 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

Sep 24, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 3, 2025, 10:22 PM EDT - 7 months ago

NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 7 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Aug 21, 2025, 2:41 AM EDT - 8 months ago

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Aug 18, 2025, 8:00 AM EDT - 8 months ago

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

Aug 6, 2025, 7:00 AM EDT - 8 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Jul 30, 2025, 8:25 AM EDT - 8 months ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 22, 2025, 8:00 AM EDT - 9 months ago

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

Jun 9, 2025, 7:00 AM EDT - 10 months ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 5, 2025, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

May 27, 2025, 8:00 AM EDT - 11 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 14, 2025, 8:00 AM EDT - 11 months ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 11 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 7, 2025, 7:15 AM EDT - 11 months ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Mar 31, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 28, 2025, 11:26 PM EST - 1 year ago

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Feb 28, 2025, 10:48 AM EST - 1 year ago

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

Feb 26, 2025, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Dec 13, 2024, 5:16 PM EST - 1 year ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 11, 2024, 9:37 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 11, 2024, 1:33 PM EST - 1 year ago

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

Dec 10, 2024, 4:34 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 11:14 AM EST - 1 year ago

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

Dec 10, 2024, 7:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Nov 18, 2024, 3:20 PM EST - 1 year ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Oct 28, 2024, 4:30 PM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Oct 4, 2024, 12:09 PM EDT - 1 year ago

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Aug 30, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 1:33 PM EDT - 1 year ago

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Jul 26, 2024, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 8, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 5, 2024, 1:40 PM EDT - 1 year ago

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

Apr 9, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 2 years ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 1, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Mar 25, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 12, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

masonat Apr. 3 at 1:34 PM

1 · Reply

TrendEdgeLogan Mar. 31 at 5:21 PM

$GH $KYMR $IMNM $NAMS $SOPH OCS PVLA ZYM SRZN ^^ best of the best healthcare / biotech names right now

0 · Reply

HAGAKURE Mar. 31 at 4:04 PM

$NAMS no revenues, no earnings … nothing here !!! Why such value ???

0 · Reply

masonat Mar. 31 at 11:51 AM

$NAMS This AI gives prevail just 37% probability of success. Always good to read the bear case to test your thesis. https://warpspeed.sh/forecast/exp-nams

1 · Reply

masonat Mar. 29 at 12:55 PM

0 · Reply

Phasedrei Mar. 29 at 8:06 AM

1 · Reply

Phasedrei Mar. 29 at 8:02 AM

0 · Reply

Phasedrei Mar. 28 at 5:35 PM

1 · Reply

masonat Mar. 28 at 12:14 PM

$NAMS Anacetrapib increased HDL 100%+ Longer follow-up showed *more* benefit, not less. Of course, the MACE benefit was largely driven by LDL, but the high HDL didn't have any negative impact.

0 · Reply

Phasedrei Mar. 28 at 10:33 AM

0 · Reply

masonat Mar. 26 at 2:12 AM

$NAMS Caveats with very different trial populations, but this might be a bigger differentiator than I was giving it credit for?

0 · Reply

newfguy Mar. 25 at 10:25 PM

$NAMS MRK acquisition of Terns refocusing market on Pharma M&A candidates. bullish for NAMS

0 · Reply

masonat Mar. 25 at 6:15 PM

$NAMS Finally published on the renal benefit that was observed in Broadway and Brooklyn.

1 · Reply

masonat Mar. 25 at 2:35 PM

$NAMS If obicetrapib shows 20%+ MACE benefit (or even 15%+, honestly), you really have to wonder why anyone would choose anything over obi. In combination, sure. But if you only have to choose one?

1 · Reply

newfguy Mar. 23 at 6:49 PM

$NAMS oversold

1 · Reply

Finlay2 Mar. 16 at 5:47 PM

$NAMS The Peter Attia Drive podcast just dropped a 50 minute special episode all about Obicetrapib. Recommend giving it a listen. Let me know your thoughts

4 · Reply

augie0030 Mar. 14 at 12:42 AM

$ESPR shorts should move on to $NAMS now that the esperion short thesis is no longer a viable play and we are launching to the moon

0 · Reply

wRsYUeX Mar. 13 at 10:15 PM

$ESPR If we had a top tier CEO with credibility with Research Analysts and Institutional Shareholders, at minimum, we would have similar valuation as $NAMS. The Board of Directors is stacked with former colleagues and appointees of Sheldung. We all know who they are an they know what disservice they are doing to ESPR Shareholders.

1 · Reply

kemah Mar. 13 at 6:02 PM

$ESPR $NAMS New Amsterdam Pharma sits at a $3.5B market cap — 7× larger than $ESPR. They have no approved drug, no revenue, and are still in trials. Meanwhile $ESPR has an approved product and sales… yet trades at a fraction of the valuation. 7× the value for a company selling nothing. Let that sink in.

2 · Reply

masonat Mar. 9 at 1:18 PM

$NAMS Watch out for the SPINOZA trial 👀 That's about all the additional details so far 🤷🏻

0 · Reply

outlawinvestor1 Mar. 9 at 1:00 PM

$NAMS ceo hinting that ada + mace data may not be that great with $MRK's enlicitide. keep an eye out for this data drop.

2 · Reply

newfguy Mar. 6 at 4:43 PM

$NAMS volume down today. thank you weak hands!

0 · Reply

Market Cap	3.79B
Revenue (ttm)	22.50M
Net Income (ttm)	-203.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-905.87%
Debt to Equity Ratio	0.00

Volume	725,300
Avg Vol	780,656
Day's Range	N/A - N/A
Shares Out	114.98M
Stochastic %K	91%
Beta	0.13
Analysts	Strong Sell
Price Target	$49.92